本帖最后由 老马 于 2012-1-13 21:20 编辑
' e6 i$ g+ D1 I3 _. A) \1 A
' q' L( _! l/ d+ S4 Y爱必妥和阿瓦斯丁的比较
/ E2 L8 d8 u5 e7 L
+ I9 _; v" ~$ ^% F% L0 Lhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
% j0 ]" |# @( z. d
7 P% M- j; `7 I9 S& L! n
4 F' o- Y8 Z6 O% V. hhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
, G0 S3 c/ B, Y! A5 f& r, w+ x==================================================1 ~% V0 j" X, D) d* p
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)& O: j" |% x! |# w, Y% M5 w2 f
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.# J. d0 t$ J( ^- w( C9 J" I
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.+ M3 o" }* u/ }! f# O- f
|